Amyloid is misfolded protein that clumps into stable, insoluble deposits. In the context of the brain this usually means beta-amyloid (Aβ), which forms extracellular plaques — one of the main hallmarks of Alzheimer’s disease.
What amyloid and beta-amyloid are
Beta-amyloid is formed when the precursor protein APP is cleaved. Its fragments clump into soluble oligomers and then into dense extracellular plaques between neurons. It is important to distinguish amyloid (outside the cells) from tau protein, which forms tangles inside neurons. Many researchers believe the soluble oligomers are more toxic than the plaques themselves.
The amyloid hypothesis: proven and disputed
The amyloid hypothesis (since 1992) proposes that the accumulation of Aβ triggers a cascade leading to neurodegeneration. Honestly about the weak points: amyloid is found in some cognitively healthy older people, the link between the number of plaques and the severity of symptoms is weak, and many anti-amyloid drugs have failed. At the same time, the new antibodies (lecanemab, donanemab) clear amyloid and modestly slow decline — this partly confirms the hypothesis but does not make it the only explanation.
Amyloid as a biomarker
Amyloid can be assessed during life: PET with amyloid tracers, the level of Aβ42 in cerebrospinal fluid, and also new blood tests. In pathology, the extent of amyloid is described by Thal phases. Amyloid biomarkers are used for early diagnosis and staging, but their presence alone is not equivalent to a diagnosis of dementia.
Calculate using this marker
Calculators where Amyloid (β-amyloid) is used directly:
Frequently asked questions
If amyloid was found in me, does it mean I will get Alzheimer’s?
Not necessarily. Amyloid deposits are also found in cognitively healthy older people. The presence of amyloid raises the risk but is not equivalent to a diagnosis of dementia — both symptoms and other biomarkers are assessed.
Do drugs really clear amyloid?
Yes, the new antibodies (lecanemab, donanemab) markedly reduce the amount of amyloid in the brain and modestly slow progression in the early stages. But the effect is modest, there are risks (swelling and microbleeds), and they are not suitable for everyone.
Related terms
Sources
- Inconsistencies and Controversies Surrounding the Amyloid Hypothesis (PMC)
- Comparison of Aβ amyloid pathology staging systems (PMC)